Infectious Disease: Strategic Biosimulation Services

Certara has conducted more than 80 projects in infectious disease, including many HIV and HCV viral dynamics/kinetics modeling projects over the past decade, in all clinical development phases. We have covered critical issues in trial design, dose selection, and development strategy. We also have helped achieve IND approval for two systemic antibiotics. Our recent experience covers most mechanisms of action including protease inhibitors, NNRTIs, NRTIs, and novel mechanisms. In addition, Certara has taken a leadership role at over a dozen industry conferences, has published in peer-reviewed journals, and has other publications and collaborations in progress.

Number and types of projects

  • 83 projects since 2005
  • Type - antibodies, peptides, lipopeptides, small molecules
  • Mechanisms of action - HRV inhibitor, β-lactamase inhibitor, cyclophilin inhibitor, fabl inhibitor, HIV integrase inhibitor, NNRTI, CCR5 antagonist, HCV protease inhibitor, NS3 protease inhibitor, RNA polymerase inhibitor, LEDGF inhibitor, anthrax toxin inhibitor/immune system enhancer, p37 envelope protein inhibitor
  • Disease areas
    • Genotype 1-4 HCV infection
    • HIV-1 infection
    • HBV infection
    • Complicated urinary tract infection (cUTI)
    • Human monkeypox
    • Respiratory syncytial virus infection
    • Severe sepsis and coagulopathy
    • Shiga toxin-producing Escherichia Coli hemolytic uremic syndrome (STEC-HUS)
    • Skin infections
    • Staphylococcus aureus infections
    • Community-acquired bacterial pneumonia
    • Severe infections due to multidrug resistant Gram-negative bacteria
    • Complicated intra abdominal infections, MRSI infections
    • Prevention of Staphylococcus aureus nasal carriage

Certara Strategic Consulting uses the power of biosimulation technology to help our clients maximize knowledge of drug safety and efficacy for anti-infectives.